{
  "id": "58db9aa28acda34529000018",
  "type": "yesno",
  "question": "Does PCSK9 (Proprotein convertase subtilisin/kexin type 9) binds with HDL-receptor (HDL-R)?",
  "ideal_answer": "No, Proprotein Convertase Subtilisin Kexin 9 (PCSK9) binds with LDL-receptor (LDL-R) causing its degradation in the lysosome with the result of LDL-C accumulating in the blood.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27284008",
    "http://www.ncbi.nlm.nih.gov/pubmed/26040332",
    "http://www.ncbi.nlm.nih.gov/pubmed/20529551",
    "http://www.ncbi.nlm.nih.gov/pubmed/23675525",
    "http://www.ncbi.nlm.nih.gov/pubmed/26318398",
    "http://www.ncbi.nlm.nih.gov/pubmed/23400816",
    "http://www.ncbi.nlm.nih.gov/pubmed/25649668",
    "http://www.ncbi.nlm.nih.gov/pubmed/26256967",
    "http://www.ncbi.nlm.nih.gov/pubmed/22683370",
    "http://www.ncbi.nlm.nih.gov/pubmed/23690465",
    "http://www.ncbi.nlm.nih.gov/pubmed/24164109",
    "http://www.ncbi.nlm.nih.gov/pubmed/21692990",
    "http://www.ncbi.nlm.nih.gov/pubmed/23974119",
    "http://www.ncbi.nlm.nih.gov/pubmed/21122852",
    "http://www.ncbi.nlm.nih.gov/pubmed/23261172",
    "http://www.ncbi.nlm.nih.gov/pubmed/25679794",
    "http://www.ncbi.nlm.nih.gov/pubmed/26495026",
    "http://www.ncbi.nlm.nih.gov/pubmed/24094767",
    "http://www.ncbi.nlm.nih.gov/pubmed/18436719",
    "http://www.ncbi.nlm.nih.gov/pubmed/21497351",
    "http://www.ncbi.nlm.nih.gov/pubmed/22580899",
    "http://www.ncbi.nlm.nih.gov/pubmed/17702855",
    "http://www.ncbi.nlm.nih.gov/pubmed/20716520",
    "http://www.ncbi.nlm.nih.gov/pubmed/26056005",
    "http://www.ncbi.nlm.nih.gov/pubmed/23141813",
    "http://www.ncbi.nlm.nih.gov/pubmed/22300679",
    "http://www.ncbi.nlm.nih.gov/pubmed/25463543",
    "http://www.ncbi.nlm.nih.gov/pubmed/24685817",
    "http://www.ncbi.nlm.nih.gov/pubmed/25905719",
    "http://www.ncbi.nlm.nih.gov/pubmed/26548330",
    "http://www.ncbi.nlm.nih.gov/pubmed/24603306",
    "http://www.ncbi.nlm.nih.gov/pubmed/22907332",
    "http://www.ncbi.nlm.nih.gov/pubmed/26088304",
    "http://www.ncbi.nlm.nih.gov/pubmed/19828345",
    "http://www.ncbi.nlm.nih.gov/pubmed/26364362",
    "http://www.ncbi.nlm.nih.gov/pubmed/23106476",
    "http://www.ncbi.nlm.nih.gov/pubmed/26023080",
    "http://www.ncbi.nlm.nih.gov/pubmed/17493938",
    "http://www.ncbi.nlm.nih.gov/pubmed/22176652",
    "http://www.ncbi.nlm.nih.gov/pubmed/25744035",
    "http://www.ncbi.nlm.nih.gov/pubmed/25070550",
    "http://www.ncbi.nlm.nih.gov/pubmed/26195630",
    "http://www.ncbi.nlm.nih.gov/pubmed/25971287",
    "http://www.ncbi.nlm.nih.gov/pubmed/24144304"
  ],
  "snippets": [
    {
      "text": "Recently it was revealed that the secreted Proprotein Convertase Subtilisin Kexin 9 (PCSK9) binds with LDL-receptor (LDL-R) causing its degradation in the lysosome with the result of LDL-C accumulating in the blood.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25679794",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The major goal of this study is to identify peptide/s from the catalytic domain of hPCSK9 that can block the binding of hPCSK9 and LDL-R and therefore can reduce LDL-R degradation leading to the clearance of LDL-C from the plasma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25679794",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vitro administration of SRT3025 to cultured AML12 hepatocytes attenuated Pcsk9 secretion and its binding to Ldlr, thereby reducing Pcsk9-mediated Ldlr degradation and increasing Ldlr expression and LDL uptake.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603306",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9), which involves in low-density lipoprotein cholesterol (LDL-C) metabolism by interacting with the LDL receptor, is considered as a potent therapeutic target for treating hypercholesterolemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Taken together, these results suggested that the IgG1-PA4 can be served as a potential candidate for the treatment of hypercholesterolemia by inhibiting PCSK9-mediated degradation of cell surface LDLRs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26056005",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor, escorting it to\u00a0its destruction in the lysosome and thereby preventing the recirculation of the low-density lipoprotein receptor to the hepatocyte cell surface. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088304",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, statins have low efficiency because they also increase PCSK9 which targets LDLR for degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26318398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibition of the enzyme PCSK9 (proprotein convertase subtilisin/kexin type 9), which is involved in depletion of the LDL-receptor, is a new pharmacologic approach. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26364362",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin kexin type 9 (PCSK9) modulates LDL-c through post-translational degradation of the LDLR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495026",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mechanistically, hepatic S1P KD was shown to decrease the liver and plasma levels of the protein proprotein convertase subtilisin/kexin type 9 (PCSK9), which degrades LDLR protein. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495026",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report here the development of sdAbs targeting human PCSK9 (proprotein convertase subtilisin/kexin type 9) as an alternative to anti-PCSK9 mAbs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27284008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) protein plays an important role in LDL cholesterol (LDL-C) metabolism, due to its role in the degradation of the LDL receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24164109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to LDL receptors, leading to their degradation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24094767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds LDL receptors, targeting them for degradation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23141813",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor and targets it for degradation, has emerged as an important regulator of serum cholesterol levels and cardiovascular disease risk",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26023080",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLR) at the cell surface and disrupts the normal recycling of the LDLR",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22683370",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase, subtilisin/kexin type 9 (PCSK9), a key regulator of plasma LDL-cholesterol (LDL-c) and cardiovascular risk, is produced in liver and secreted into plasma where it binds hepatic LDL receptors (LDLR), leading to their degradation",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20716520",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the hepatic low-density lipoprotein receptor (LDL-R) and is therefore a prominent therapeutic target for reducing LDL-cholesterol",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25744035",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the present study we scanned the related gene of a clinically diagnosed autosomal genetic hypercholesterolemia family for the possible mutations and established eukaryotic expression vector of mutation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene with gene recombination technique to investigate the contributions of the variation on low density lipoprotein receptor (LDL-R) metabolism and function alternation.Mutation detection was conducted for LDL-R, apolipoprotein B(100) (apoB(100)) and PCSK9 gene with nucleotide sequencing in a Chinese FH family",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20529551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin-kexin type 9 (PCSK9) provides a key step in LDL metabolism by stimulating LDL receptor degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The proprotein convertase subtilisin-kexin type 9 (PCSK9) pathway plays a key role in lipoprotein metabolism by promoting LDL-receptor degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23261172",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin-kexin type 9 (PCSK9) plays a key role in LDL receptor processing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21122852",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment.We developed a sandwich ELISA using recombinant human PCSK9 protein and 2 affinity-purified polyclonal antibodies directed against human PCSK9.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18436719",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin kexin type 9 (PCSK9) enhances the degradation of the LDLR and modulates liver CD81 levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low-density lipoprotein (LDL) metabolism is governed by proprotein convertase subtilisin-kexin type 9 (PCSK9), which down-regulates LDL receptor expression, resulting in higher LDL cholesterol (LDL-C).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23106476",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin kexin type 9 (PCSK9) is gaining attention as a key regulator of serum LDL-cholesterol (LDLC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17702855",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The proprotein convertase subtilisin/kexin type 9 (PCSK9) gene regulates cholesterol homoeostasis by accelerating low-density lipoprotein receptor (LDLR) degradation resulting in the decreased catabolism of low-density lipoprotein (LDL) leading to hypercholesterolaemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25649668",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted protein that binds to the epidermal growth factor-like-A domain of the low density lipoprotein receptor (LDLR) and mediates LDLR degradation in liver.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400816",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a regulator of LDL-cholesterol receptor homeostasis and emerges as a therapeutic target in the prevention of cardiovascular (CV) disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24685817",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The present study was conducted to investigate the role of plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels, a regulator of LDL-receptor expression, in the occurrence of diabetic dyslipidemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21497351",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.uniprot.org/uniprot/PCSK9_SAIBB",
    "http://www.uniprot.org/uniprot/PCSK9_MACMU",
    "http://www.uniprot.org/uniprot/PCSK9_PANTR",
    "http://www.uniprot.org/uniprot/PCSK9_COLGU",
    "http://www.uniprot.org/uniprot/PCSK9_CALJA",
    "http://www.uniprot.org/uniprot/PCSK9_LAGLA",
    "http://www.uniprot.org/uniprot/PCSK9_SAGLB",
    "http://www.uniprot.org/uniprot/PCSK9_HUMAN",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D043484",
    "http://www.uniprot.org/uniprot/PCSK9_PONPY",
    "http://amigo.geneontology.org/amigo/term/GO:1990666",
    "http://www.uniprot.org/uniprot/PCSK9_MACNE",
    "http://www.uniprot.org/uniprot/PCSK9_RAT",
    "http://www.uniprot.org/uniprot/PCSK9_ATEGE",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000071449",
    "http://www.uniprot.org/uniprot/PCSK9_PANPA",
    "http://www.uniprot.org/uniprot/PCSK9_PLEMO"
  ],
  "exact_answer": "Yes"
}